204 Results for "

ABT

" in MedChemExpress (MCE) Product Catalog:
Products (204)

204 Results for "ABT" in MCE Product Catalog:

251
251 Publications Verification
Cat. No.: HY-15531
CAS No.: 1257044-40-8
Purity:  99.95%
Synonyms: ABT-199; GDC-0199; RG7601
Target:  

Bcl-2 Family Autophagy

Research Areas:  

Cancer

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy .
loading...
    loading...
158
158 Cited Publications
Cat. No.: HY-10087
CAS No.: 923564-51-6
Purity:  99.72%
Synonyms: ABT-263
Target:  

Bcl-2 Family

Research Areas:  

Cancer

Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
loading...
    loading...
158
158 Cited Publications
Cat. No.: HY-10087A1
CAS No.: 1093851-28-5
Synonyms: ABT-263 dihydrochloride
Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a Ki value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases .
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-50907
CAS No.: 852808-04-9
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-10129
CAS No.: 912444-00-9
Purity:  99.78%
Synonyms: ABT-888
Target:  

PARP Autophagy

Research Areas:  

Cancer

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively .
loading...
    loading...
51
51 Cited Publications
Cat. No.: HY-10130
CAS No.: 912445-05-7
Purity:  99.98%
Synonyms: ABT-888 dihydrochloride
Target:  

PARP Autophagy

Research Areas:  

Cancer

Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-90001
CAS No.: 155213-67-5
Synonyms: ABT 538; RTV
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.61 μM. Ritonavir (ABT 538) can penetrate the blood brain barrier (BBB) .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-19569
CAS No.: 1310726-60-3
Synonyms: ABT-494
Target:  

JAK

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-14588
CAS No.: 192725-17-0
Purity:  99.71%
Synonyms: ABT-378
Target:  

HIV HIV Protease SARS-CoV

Research Areas:  

Infection Neurological Disease Cancer

Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 14.2 μM .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-13998
CAS No.: 1132935-63-7
Purity:  98.17%
Synonyms: ABT-333
Target:  

HCV DNA/RNA Synthesis

Research Areas:  

Infection

Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-12594
CAS No.: 1216941-48-8
Purity:  99.87%
Synonyms: ABT-450; Veruprevir
Target:  

HCV Protease HCV SARS-CoV

Research Areas:  

Infection

Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-103389
CAS No.: 1614-12-6
Purity:  99.88%
Synonyms: ABT; 3-Aminobenzotriazole
Target:  

Cytochrome P450

Research Areas:  

Cancer

1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of cytochrome P450 (P450).
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-17634
CAS No.: 1365970-03-1
Synonyms: ABT-493
Target:  

HCV HCV Protease SARS-CoV

Research Areas:  

Infection

Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 4.09 μM .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-13997
CAS No.: 1258226-87-7
Purity:  98.59%
Synonyms: ABT-267
Target:  

HCV

Research Areas:  

Infection

Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15403
CAS No.: 173937-91-2
Purity:  99.58%
Synonyms: ABT-627; (+)-A 127722; A-147627
Atrasentan (ABT-627) is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15403A
CAS No.: 195733-43-8
Purity:  99.82%
Synonyms: ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride
Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC50 of 0.0551 nM for ETA .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14814
CAS No.: 189279-58-1
Purity:  99.95%
Synonyms: RX-3341; WQ-3034; ABT492
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-14814A
CAS No.: 352458-37-8
Purity:  99.87%
Synonyms: ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-103161
CAS No.: 1188890-28-9
Purity:  99.64%
Target:  

Adenosine Kinase

Research Areas:  

Inflammation/Immunology

ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC50=1.7 nM).
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-50751
CAS No.: 796967-16-3
Synonyms: ABT-869; AL-39324
Research Areas:  

Cancer

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .
loading...
    loading...